- Home
- COCP vs CANF Comparison
COCP vs CANF Comparison
Compare COCP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- CANF
- Stock Information
- Founded
- COCP 2006
- CANF 1994
- Country
- COCP United States
- CANF Israel
- Employees
- COCP N/A
- CANF N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- CANF Health Care
- Exchange
- COCP Nasdaq
- CANF Nasdaq
- Market Cap
- COCP 15.7M
- CANF 13.5M
- IPO Year
- COCP N/A
- CANF N/A
- Fundamental
- Price
- COCP $1.80
- CANF $1.03
- Analyst Decision
- COCP Strong Buy
- CANF Strong Buy
- Analyst Count
- COCP 1
- CANF 2
- Target Price
- COCP $6.00
- CANF $14.00
- AVG Volume (30 Days)
- COCP 21.6K
- CANF 146.4K
- Earning Date
- COCP 08-13-2025
- CANF 08-29-2025
- Dividend Yield
- COCP N/A
- CANF N/A
- EPS Growth
- COCP N/A
- CANF N/A
- EPS
- COCP N/A
- CANF N/A
- Revenue
- COCP N/A
- CANF $674,000.00
- Revenue This Year
- COCP N/A
- CANF $461.72
- Revenue Next Year
- COCP N/A
- CANF N/A
- P/E Ratio
- COCP N/A
- CANF N/A
- Revenue Growth
- COCP N/A
- CANF N/A
- 52 Week Low
- COCP $1.12
- CANF $0.98
- 52 Week High
- COCP $3.26
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- COCP 69.71
- CANF 43.30
- Support Level
- COCP $1.46
- CANF $1.00
- Resistance Level
- COCP $1.60
- CANF $1.09
- Average True Range (ATR)
- COCP 0.08
- CANF 0.03
- MACD
- COCP 0.02
- CANF 0.00
- Stochastic Oscillator
- COCP 92.31
- CANF 45.00
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).